Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis

Data de publicação: Data Ahead of Print:

Unidades de investigação

Abstract

Lay Summary We performed a systematic review and meta-analysis of randomized controlled trials in Crohn's disease with the primary objective of assessing therapeutic histologic outcomes (response and remission). Our results show that CD therapies are effective in achieving these outcomes. Background The effectiveness of Crohn's disease treatments for inducing histological outcomes has not been addressed systematically. We performed a systematic review and meta-analysis of randomized controlled trials in Crohn's disease to assess the impact of therapies on mucosal histopathology. Methods Databases (MEDLINE, CENTRAL, Web of Science, EMBASE) were searched for randomized controlled trials including adult patients and evaluating histological outcomes. Risk of bias was evaluated using the Critical Appraisal Skills Programme. Histological outcomes, pooled frequencies, pooled odds ratios, and standard mean differences of the histological scores were compared between the intervention and placebo groups using a random-effects model. Results Out of 2070 records, 10 studies were included. The quality of the studies ranged from moderate to high, but they were clinically and methodologically diverse. All interventions were superior to placebo. Histological response was achieved by 68% of patients, and 38% achieved remission. Pooled odds ratio for histological remission in patients receiving intervention vs placebo was 4.14 (95% CI, 2.28-7.50; I-2 0%; P < .01). Heterogeneity in histological response estimates was significant, and subgroup analysis of the odds ratio results was limited by the low number of studies per group. The standard mean difference of histological scores was higher for patients receiving intervention in both induction and maintenance studies (-2.95; 95% CI, -4.17 to -1.74; I-2 83% P < .00; and -2.58; 95% CI, -3.89 to -1.27; I-2 56% P < .00). Conclusions Crohn's disease therapies are effective for achieving histological outcomes. Adherence to recently published consensus on histopathology harmonization assessment in Crohn's disease would facilitate adequate comparison between studies in the future.

Dados da publicação

ISSN/ISSNe:
1078-0998, 1536-4844

Inflammatory Bowel Diseases  Oxford University Press

Tipo:
Review
Páginas:
1231-1243
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 5

Citações Recebidas na Scopus: 6

Documentos

  • Não há documentos

Métricas

Filiações

Filiações não disponíveis

Keywords

  • histological outcomes; histological healing; treatment response

Proyectos asociados

Gut microbiome and IBD therapy: an interplay?

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (GutIBD) . 2021

Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (IronIBD) . 2021

Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.

Investigador Principal: Fernando José Magro Dias

Estudo Observacional Académico (4WARD) . 2021

Isolated Ulceration of Crohn’s Anastomosis

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2021

Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2022

Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2021

Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação